Filing Details
- Accession Number:
- 0001209191-21-020782
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-16 16:20:29
- Reporting Period:
- 2021-03-15
- Accepted Time:
- 2021-03-16 16:20:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1347178 | Vanda Pharmaceuticals Inc. | VNDA | Pharmaceutical Preparations (2834) | 030491827 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1785894 | Ii Aranthan Jones | C/O Vanda Pharmaceuticals Inc. 2200 Pennsylvania Avenue, Suite 300E Washington DC 20037 | Chief Corp. Affairs Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-03-15 | 15,000 | $11.32 | 111,935 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-03-15 | 18,000 | $17.72 | 93,935 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2021-03-15 | 15,000 | $0.00 | 15,000 | $11.32 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
55,000 | 2030-02-25 | No | 4 | M | Direct |
Footnotes
- A portion of the shares were sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $17.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date